DESCRIBE the prevalence of and burden associated with anemia in patients with CKD, including those who are hyporesponsive to ESA therapy.
DESCRIBE the prevalence of and burden associated with anemia in patients with CKD, including those who are hyporesponsive to ESA therapy. Strongly agree
DESCRIBE the prevalence of and burden associated with anemia in patients with CKD, including those who are hyporesponsive to ESA therapy. Agree
DESCRIBE the prevalence of and burden associated with anemia in patients with CKD, including those who are hyporesponsive to ESA therapy. Neutral
DESCRIBE the prevalence of and burden associated with anemia in patients with CKD, including those who are hyporesponsive to ESA therapy. Disagree
DESCRIBE the prevalence of and burden associated with anemia in patients with CKD, including those who are hyporesponsive to ESA therapy. Strongly disagree
DISCUSS the pathogenic mechanisms involved in anemia associated with CKD, including the roles of inflammation, hepcidin, and the HIF pathway.
DISCUSS the pathogenic mechanisms involved in anemia associated with CKD, including the roles of inflammation, hepcidin, and the HIF pathway. Strongly agree
DISCUSS the pathogenic mechanisms involved in anemia associated with CKD, including the roles of inflammation, hepcidin, and the HIF pathway. Agree
DISCUSS the pathogenic mechanisms involved in anemia associated with CKD, including the roles of inflammation, hepcidin, and the HIF pathway. Neutral
DISCUSS the pathogenic mechanisms involved in anemia associated with CKD, including the roles of inflammation, hepcidin, and the HIF pathway. Disagree
DISCUSS the pathogenic mechanisms involved in anemia associated with CKD, including the roles of inflammation, hepcidin, and the HIF pathway. Strongly disagree
REVIEW outcomes from clinical trials evaluating the use of HIF-PHIs to treat anemia in patients with CKD
REVIEW outcomes from clinical trials evaluating the use of HIF-PHIs to treat anemia in patients with CKD Strongly agree
REVIEW outcomes from clinical trials evaluating the use of HIF-PHIs to treat anemia in patients with CKD Agree
REVIEW outcomes from clinical trials evaluating the use of HIF-PHIs to treat anemia in patients with CKD Neutral
REVIEW outcomes from clinical trials evaluating the use of HIF-PHIs to treat anemia in patients with CKD Disagree
REVIEW outcomes from clinical trials evaluating the use of HIF-PHIs to treat anemia in patients with CKD Strongly disagree